CHOP Researchers Develop Allogeneic CART for Relapsed or Refractory T-ALL Using Base Editing
May 23, 2022
CHOP researchers have tested and developed an “off-the-shelf” chimeric antigen receptor T-cell (CART) using base editing.
Your child will be cared for by one of the most accomplished teams of childhood cancer experts in the world. We provide medical care, emotional counseling and much more. We make sure your child, you and every family member get the highest level of support.
May 23, 2022
CHOP researchers have tested and developed an “off-the-shelf” chimeric antigen receptor T-cell (CART) using base editing.
May 11, 2022
Emily Whitehead, now 17, received life-saving treatment at CHOP, transforming the field of cancer immunotherapy.
May 11, 2022
Whitehead received life-saving treatment at CHOP, under the care of Dr. Stephan Grupp, transforming the field of cancer immunotherapy.
May 5, 2022
Drs. Yael Mossé and Sogol Mostoufi-Moab were recognized at the 2022 ASPHO Conference for their outstanding contributions in the field of pediatric oncology.
Apr 5, 2022
Adolescents and young adults (AYA) with cancer have unique emotional and social needs. Meet a clinical psychologist who is focused on strategies to help AYAs manage their own health and medications.
Apr 20, 2023
CHOP’s Cancer Center provides special services for adolescent and young adult (AYA) patients. Meet some of those patients and learn about their journeys.
Apr 1, 2022
CHOP researchers have found that multidrug resistant tumors have reduced connections between mitochondria and endoplasmic reticulum, causing signaling dysfunction.
Mar 28, 2022
A transformative gift from local philanthropists Steve and Susan Kelly launches first-of-its-kind hub for pediatric cancer immunotherapy.
Mar 18, 2022
More than 250 experts gathered in Philadelphia and virtually to discuss the latest scientific advancements and breakthroughs in pediatric precision medicine oncology.
Mar 14, 2022
CHOP researchers have shown that linking a tumor-killing prodrug to a macromolecular carrier of the Poloxamer family improves retention of the drug in treatment-resistant neuroblastoma tumors.